In conclusion, PNPLA3 and TM6SF2 genetic polymorphisms do not appear as major determinants of liver scarring in Pakistani patients with CHC and may be of more relevance to CLP with dysregulated hepatic fat such as NAFLD. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.